Overview BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer Status: Terminated Trial end date: 2008-08-01 Target enrollment: Participant gender: Summary Phase II study of lapatinib and gemcitabine for patients with metastatic pancreatic cancer. Phase: Phase 2 Details Lead Sponsor: Brown UniversityCollaborators: Memorial Hospital of Rhode IslandRhode Island HospitalThe Miriam HospitalTreatments: GemcitabineLapatinib